Please Wait...

Effects of Partial Volume Differences Between Time points on Longitudinal Amyloid SUVR Measurements

Gregory Klein, Joël Schaerer, Florent Roche, Mehul Sampat, Gennan Chen, Joyce Suhy Bioclinica, Newark, CA, USA; Bioclinica, Lyon, France


Introduction

Longitudinal analyses of amyloid PET data using a standard uptake value ratio (SUVR) and volume of interest (VOI) approach implicitely assume that the VOIs sample comparable regions at all imaging time points. It is known, however, that considerable volumetric changes can take place during a one-two year interval between PET imaging time points in a clinical trial. Annual cerebral atrophy rates of 2.37% have been reported for the Alzheimer's disease (AD) group, and 0.41%  for a control group1. These volumetric changes can not only change the size and shape of each region, but also can change the relative partial volume effects of white matter and CSF areas adjacent to grey matter within a sampling region. A native space approach using VOIs separately defined from time-matched MRI data can help to minimize differences in VOI shape and size, however, a partial volume approach is needed to address differences in relative partial volume contributions. This work investigates the extent of change in partial volume between time points in subjects with AD, Mild Cognitive Impairment (MCI) and Normal Controls (NC).

Methods

Freesurfer (X-sectional / version 5.3) was used to obtain VOI segmentations on T1 MRI data from 270 Alzheimer's Disease Neuroimaging Initiative  (ADNI) subjects (23 with probable AD, 145 with MCI and 102 NC) at two time points approximately 24 months apart. Following the partial volume correction (PVC) approach of Müeller-Gärtner2, Freesurfer segmentations at baseline (TP1) and follow-up (TP2) were used to produce two three-tissue segmentations of grey matter(GM), white matter(WM) and CSF for each subject. Segmentations were smoothed to the same resolution of the PET and the partial volume contributions of each tissue type were computed for each Freesurfer region. Partial volume components of the composite and regional cortical areas were computed, and also for the reference regions to separately analyse longitudinal behaviour of the numerator and denominator components of the SUVR. Florbetapir PET data at matching time points were registered to the MRI data in T1 native space, and composite SUVR's were computed using a grouping of four larger cortical regions, equally weighted as described by Landau3. Twelve potential SUVR reference regions were evaluated including whole cerebellum, cerebellar grey (CG), corpus callosum (CC) and subcortical white matter (SWM).  SUVRs were computed with and without PVC.

Conclusions

Results indicate that changing partial volume effects in the cortical target regions and reference regions used in a VOI-based SUVR analysis can bias longitudinal results. Care must be taken in interpreting SUVR changes that may be influenced by extent of volumetric changes, particularly in the AD subject group.

References

  1. Fox et al. Arch Neurol 2000;57:339-344.
  2. Müeller-Gärtner et al. J Cereb Blood Flow 1992, 12:571-583.
  3. Landau et al. J Nucl Med 2013; 54:1–8.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

ASCPT 2018 Annual Meeting https://t.co/i0mjYbBq5N Join @Bioclinica Research's Open House 3/22 https://t.co/citlLotbD7
bioclinica (2 days ago)
Heading to DC for DIA's #Pharmacovigilance & Risk Mgmt Strategies Conf.? Visit @Bioclinica in booth 32. Preview our… https://t.co/alU1sCg04l
bioclinica (2 days ago)
Kevin Bishop, named a 'Top Innovator' in #clinicaltrials by @CenterWatch See how we're reducing risk to the clinic… https://t.co/rXBGvIh9Wr
bioclinica (3 days ago)
RT @CenterWatch: Congratulations to all our #2018TopInovators! Read about the innovations in the #CWMonthly special edition, https://t.co/Y…
bioclinica (2 weeks ago)
RT @CenterWatch: .@Pfizer demonstrates leadership in #clinicaltrial innovation with two spots on the @CenterWatch #2018TopInnovators, https…
bioclinica (2 weeks ago)
RT @jheanne: I just contributed towards 'Joby' on https://t.co/EHt69JFLZ9 Best wishes to Joby and all our @Bioclinica team members! @Oxfam…
bioclinica (2 weeks ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen